Results 131 to 140 of about 18,093 (237)

Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis. [PDF]

Crit Care, 2022
Li Bassi G, Gibbons K, Suen JY, Dalton HJ, White N, Corley A, Shrapnel S, Hinton S, Forsyth S, Laffey JG, Fan E, Fanning JP, Panigada M, Bartlett R, Brodie D, Burrell A, Chiumello D, Elhazmi A, Esperatti M, Grasselli G, Hodgson C, Ichiba S, Luna C, Marwali E, Merson L, Murthy S, Nichol A, Ogino M, Pelosi P, Torres A, Ng PY, Fraser JF, COVID-19 Critical Care Consortium.   +32 more
europepmc   +1 more source

Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aim Human T‐Lymphotropic virus type 1 (HTLV‐1) infection can lead to HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction.
Meygol Mirzaei Rezaei, Mahdi Khosravi Nia, Kasra Allaei Rouzbahani, Maryam Kazemi, Negar Asghari Hosori, Mehdi Norouzi, Farzaneh Sotoudegan, Narges Eslami, Negar Ariamand, Vahid Shahnavaz, Arash Letafati, Sayed‑Hamidreza Mozhgani   +11 more
wiley   +1 more source

Age-Specific Pharmacology of Neuromuscular Blocking Agents: A Comprehensive Review. [PDF]

Med Sci Monit
Radkowski P, Kowalczyk K, Łęczycka A, Oniszczuk H, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. [PDF]

Chem Sci, 2022
Wu Y, Liu YY, Liu HK, Yu SB, Lin F, Zhou W, Wang H, Zhang DW, Li ZT, Ma D.   +9 more
europepmc   +1 more source

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no definitive cure is currently available. As a consequence, therapeutic efforts
Raffaele Epis, Gabriele Rovetta, Giulia Ferrari, Chiara Bonfanti, Giorgia Careccia, Graziella Messina   +5 more
wiley   +1 more source

Development of the neuromuscular junction and neuromuscular blocking agents in neonates, infants and children: A narrative review. [PDF]

Eur J Anaesthesiol
Saldien V, Veyckemans F, Hansen TG.
europepmc   +1 more source

Provider variability in the intraoperative use of neuromuscular blocking agents: a retrospective multicentre cohort study. [PDF]

BMJ Open, 2021
Althoff FC, Xu X, Wachtendorf LJ, Shay D, Patrocinio M, Schaefer MS, Houle TT, Fassbender P, Eikermann M, Wongtangman K.   +9 more
europepmc   +1 more source

PRMT5 Mediates Sepsis‐Associated Lung Injury by Modulating JAK1 Arginine Methylation: A Mechanism Study

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 8, August 2026.
ABSTRACT Lung injury is a common complication in critical sepsis. PRMT5 is implicated in endothelial inflammation and lung diseases, but its role in sepsis‐associated lung injury remains unclear. This study collected clinical sepsis samples and detected the mRNA expression of PRMT5.
Bo Wang, Zhen Ge, Fei‐Xiang Chen
wiley   +1 more source

Pharmacological strategies to minimize or avoid neuromuscular blocking agents during general anesthesia: a comprehensive approach from airway management to surgical requirements. [PDF]

Front Pharmacol
Zhan FQ, Guo R.
europepmc   +1 more source

Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. [PDF]

Br J Anaesth, 2021
Weber V, Abbott TEF, Ackland GL.
europepmc   +1 more source